LuciAle 150mg (Alectinib)

Description

Overview
LuciAle 150mg is an oral capsule containing Alectinib 150 mg (as Alectinib hydrochloride 161.33 mg), manufactured by Lucius Pharmaceutical Co., Ltd., Vientiane, Laos (WHO-GMP certified). It is a highly selective, second-generation ALK (anaplastic lymphoma kinase) inhibitor used to treat ALK-positive non-small cell lung cancer (NSCLC), including disease that has spread to the brain.
LuciAle contains the same active ingredient as Alecensa® (Genentech/Roche), first approved by the US FDA in 2015.

How LuciAle 150mg Works
Alectinib selectively blocks the ALK tyrosine kinase and the RET receptor. In ALK-positive NSCLC, an abnormal ALK gene drives uncontrolled cancer cell growth. By inhibiting ALK signaling, LuciAle slows tumor progression and triggers cancer cell death. A key advantage is its ability to cross the blood-brain barrier, making it effective against brain (CNS) metastases — a common site of spread in ALK-positive lung cancer. See the full alectinib drug profile on NIH DailyMed.

Uses
LuciAle 150mg is prescribed for:

First-line treatment of adult patients with ALK-positive metastatic NSCLC (confirmed by an FDA-approved test)
Adjuvant treatment following complete tumor resection in ALK-positive NSCLC (tumors ≥4 cm or node-positive)
ALK-positive NSCLC that has progressed on or is intolerant to crizotinib
NSCLC with brain metastases, due to strong central nervous system penetration

A confirmed ALK-positive diagnosis is required before treatment begins.

Dosage
DetailInformationRecommended dose600 mg (four 150 mg capsules) orally twice daily — 1,200 mg/day totalAdministrationTake with food; swallow capsules wholeImportantDo not open or dissolve the capsulesSevere hepatic impairmentReduced to 450 mg twice dailyMissed dose / vomitingSkip it; take the next dose at the scheduled time — do not double upDurationContinue until disease progression or unacceptable toxicity (adjuvant: up to 2 years)
Always follow your oncologist’s prescription. Full prescribing details are in the official FDA label for Alecensa (alectinib). Storage: keep in a dry place at 20–25°C, away from light and out of reach of children.

Product Specifications

Active Ingredient: Alectinib 150 mg (as Alectinib HCl 161.33 mg)
Drug Class: Selective ALK / RET Tyrosine Kinase Inhibitor (second-generation)
Manufacturer: Lucius Pharmaceutical Co., Ltd., Vientiane, Laos — WHO-GMP certified
Reference Brand: Alecensa® (Genentech / Roche)
Form: Hard oral capsule

Side Effects
Common: fatigue, constipation, swelling (edema), muscle pain (myalgia), rash, cough, anemia.
Common laboratory changes: raised liver enzymes (AST/ALT), increased bilirubin, increased creatine phosphokinase (CPK), high blood sugar, low calcium.
Serious (seek medical help immediately): liver toxicity, lung inflammation (interstitial lung disease/pneumonitis), slow heartbeat (bradycardia), severe muscle pain with CPK elevation, kidney problems, hemolytic anemia.
Liver function should be monitored every 2 weeks for the first 3 months, then monthly. Avoid sun exposure and use sunscreen, as alectinib can cause photosensitivity. Not for use during pregnancy — see FAQ.

FAQ
What is LuciAle 150mg used for?
LuciAle 150mg is used to treat ALK-positive non-small cell lung cancer (NSCLC), including as first-line therapy, after surgery (adjuvant), and for cancer that has spread to the brain.
Is LuciAle the same as Alecensa?
Yes. Both contain Alectinib as the active ingredient. LuciAle is the Lucius Pharmaceutical (Laos) version of Alecensa®.
How many capsules of LuciAle 150mg do I take?
The recommended dose is 600 mg twice daily — that is four 150 mg capsules in the morning and four in the evening (eight capsules per day), taken with food.
Why must LuciAle be taken with food?
Food significantly increases the absorption of alectinib (up to 3-fold), improving effectiveness and reducing stomach-related side effects.
Does LuciAle work for brain metastases?
Yes. Alectinib crosses the blood-brain barrier and is effective against central nervous system (brain) metastases, which are common in ALK-positive NSCLC.
Do I need a test before starting?
Yes. A confirmed ALK-positive result via an FDA-approved test is required before treatment.
Can the dose be lowered for side effects?
Yes. The dose can be reduced stepwise (600 mg → 450 mg → 300 mg twice daily). Treatment is stopped if the 300 mg twice-daily dose is not tolerated. Do not adjust the dose yourself.
Is it safe during pregnancy?
No. Alectinib can harm an unborn baby. Women should use effective contraception during treatment and for 5 weeks after the last dose. Men with female partners should use contraception during and for 3 months after. Do not breastfeed during treatment and for 1 week after the last dose.
How should it be stored?
In a dry place at 20–25°C, away from light, and out of reach of children.